WO1999038553A1 - Implantable drug infusion device having an improved valve - Google Patents

Implantable drug infusion device having an improved valve Download PDF

Info

Publication number
WO1999038553A1
WO1999038553A1 PCT/US1999/002172 US9902172W WO9938553A1 WO 1999038553 A1 WO1999038553 A1 WO 1999038553A1 US 9902172 W US9902172 W US 9902172W WO 9938553 A1 WO9938553 A1 WO 9938553A1
Authority
WO
WIPO (PCT)
Prior art keywords
fluid
infusion device
drug infusion
implantable drug
valve
Prior art date
Application number
PCT/US1999/002172
Other languages
French (fr)
Other versions
WO1999038553A9 (en
Inventor
Markus Haller
Theo S. J. Lammerink
Niels Olij
Original Assignee
Medtronic, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtronic, Inc. filed Critical Medtronic, Inc.
Priority to EP99905609A priority Critical patent/EP1053036B1/en
Priority to AU25734/99A priority patent/AU2573499A/en
Priority to DE69902145T priority patent/DE69902145T2/en
Publication of WO1999038553A1 publication Critical patent/WO1999038553A1/en
Publication of WO1999038553A9 publication Critical patent/WO1999038553A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/82—Internal energy supply devices
    • A61M2205/8206—Internal energy supply devices battery-operated
    • A61M2205/8212—Internal energy supply devices battery-operated with means or measures taken for minimising energy consumption
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/22—Valves or arrangement of valves

Definitions

  • the present invention relates to the field of implantable drug infusion devices and more particularly to an implantable drug infusion device having a low power multi-stable valve capable of providing a range of flow therethrough.
  • Implantable are used to provide patients with a constant or programmable dosage or infusion of a drug or any other therapeutic agent.
  • An example of such an implantable drug infusion device currently available is the Medtronic SynchroMed drug pump.
  • Such a device includes a drug reservoir, a peristaltic pump to pump out the drug from the reservoir and a catheter port to transport the pumped out drug from the reservoir via the pump and into the patient.
  • the drug is provided into the reservoir at a very low pressure and the drug must therefore be forced out of the reservoir and into the patient by a pump.
  • This device requires a battery to power the pump as well as an electronic module to control the pump. Needless to say, because a separate pump battery and electronic module is required, the cost of this device is greater than desired.
  • An alternative design to an active pumping implantable medical device are devices which do not require the use of a separate pump, but instead rely upon a pressurized reservoir to deliver the drug.
  • An example of such a device includes the Medtronic IsoMedTM.
  • the presently available device although requiring low power, does not provide the optimal therapy to the patient.
  • all such devices currently available feature valves to control the flow of the drug which may only be in a fully open or fully closed position, for example, they are not able to be opened only half-way. The consequences of such a limited option for valve control is that the flow rate of the drug provided to the patient is either completely on or completely off.
  • the present invention provides an implantable medical pump featuring a low power multi-stable valve.
  • the present invention features a valve constructed using an electrolytic fluid, the fluid releasing a gas when subject to an electronic current, the same gas absorbed again by the fluid when such current is removed.
  • the fluid is further housed within an uniquely designed actuation chamber such that the out-gassing of the fluid deforms the membranes defining the chamber.
  • the membranes are positioned such that this deformation will inhibit or completely restrict the flow pathway between the reservoir and ultimately the patient.
  • valve has the additional safety feature of being in the normally closed position when no energy is provided.
  • pump features such a valve coupled to a flow sensor, the flow sensor thereby providing input to control the electrolytic fluid and thereby the valve position.
  • a still further embodiment provides a method of compensating for any changes in the electrolytic fluid over time caused by reduction or oxidation of the fluid. Such compensation is provided through the application of a biasing current to thereby inhibit any such reduction or oxidation of the fluid.
  • FIG. 1 is a block diagram of the present invention.
  • FIGS. 2 A and 2B are side views of a low power multi-stable valve used in the present invention, where in FIG 2A the valve is closed and in FIG. 2B the valve is opened.
  • FIG. 3 discloses the dimensions preferred in a valve constructed according to the present invention.
  • FIG. 4 depicts an alternative embodiment of the present invention.
  • FIG. 5 depicts a still further embodiment of the present invention.
  • FIG. 6 shows a further alternative embodiment of the present invention.
  • FIG. 7 depicts one problem with the long term use of an electrolytic fluid.
  • FIGS. 8 A and B depict solutions to the problem illustrated in FIG. 7
  • FIG. 9 is a block diagram of the steps used to correct any flow variance caused by the reduction of the electrolyte.
  • FIG. 10 shows an alternative embodiment of the present invention featuring a flow regulator.
  • FIG. 11 is a top view of a variable flow restrictor channel used in flow regulator.
  • FIG. 12 is a sectional view of the flow restrictor channel of FIG. 11 taken along the line 12-12
  • the FIGS, are not necessarily to scale.
  • FIG. 1 is a block diagram of the present invention.
  • a system 1 comprises a reservoir 2, valve 3, flow sensor 4, electronic controls 10, battery 11, telemetry assembly 12 and outlet catheter 5.
  • Valve 3 is coupled to the reservoir and also to flow sensor 4.
  • Flow sensor 4 is coupled, in turn to outlet catheter 5, such that fluid form reservoir 2 may be pumped through valve and out to outlet catheter.
  • Outlet catheter may be of any model desired and suited to the patient's requirements.
  • Flow sensor is controlled by electronic controls 10. These controls include, among other devices, an efficient circuit to drive the actuators used in valve 3.
  • the device may be refilled through injection port 5 through the use of a needle 6 as is well known. This refill procedure may be furtehr enhanced through the use of the system as described in the above referenced United States patent application entitled "System For Locating Implantable Medical Device” of Markus Haller and Koen Weijand (Our File: P-
  • a hermetic closure 13 Surrounding all components of the implantable flow sensor other than the outlet catheter is a hermetic closure 13 as is well known in the art.
  • FIGS. 2A and 2B are side views of a low power multi-stable valve used in the present invention.
  • the valve is shown in FIG. 2A in the closed position and in FIG. 2B in the open position.
  • valve is constructed with an upper membrane 21, a lower membrane 22 and a substrate 23.
  • Upper and lower membranes are preferably made of silicon and substrate is preferably made of Pyrex TM glass, although other materials may also be used.
  • the areas of substrate and membranes in contact with any drug or fluid are further preferably coated with diamond or diamond-like carbon so as to inhibit any interactions between the drug or fluid and the materials.
  • Such coatings may be selected according to the particular drug or fluid to be infused, and may include also tantalum or titanium, for example
  • upper membrane features a relatively thicker center portion 24 circumscribed by thin section 26. Thin section extends completely about center portion 24, but appears in two sections because in the preferred embodiment valve is circular.
  • Lower membrane features a relatively thicker mesa 35 circumscribed by thin section 30.
  • top and bottom membranes define between them actuation chamber 25. Extending from mesa is valve seat 40 which engages against and thereby provides a seal between inlet channel 41 and outlet channel 42.
  • Substrate 23 also features two electrodes 31, 33 which provide energy to the electrolytic fluid within actuation chamber 25, causing it to either undergo reduction or oxidation and thus actuate the valve.
  • electrode 31 is platinum and electrode 33 is copper. Electrodes may also be further coated so as to minimize any reduction of the fluid which may take place.
  • electrolytic fluid is a solution of copper sulfate, such that it will readily undergo oxidation and reduction with the electrodes.
  • the reversible reactions used to electrochemically actuate the valve are given by:
  • a pressure increase of 200 mbar is required to be applied.
  • a deflection of the membrane of 10 ⁇ m will increase the volume in the actuation chamber of about 2.5 ⁇ l. This volume has to be created by the production of O 2 by electrolyze of the electrolyte.
  • a pressure of 200 mbar will result in a decrease in molecular volume from 24.51/mol to 20.41/mol.
  • FIG. 2B which depicts the valve 3 opened.
  • the electrolyte positioned within actuation chamber 25 has been energized, i.e., a small amount of electricity, typically less than 2 Volts has been supplied over a sufficient time to oxidize the fluid, thereby releasing gaseous oxygen which in turn causes the membranes to deflect and thus actuate the valve.
  • a small amount of electricity typically less than 2 Volts has been supplied over a sufficient time to oxidize the fluid, thereby releasing gaseous oxygen which in turn causes the membranes to deflect and thus actuate the valve.
  • the exact amount of electricity required depends in part upon the size of the electrodes used such that a sufficient current density is achieved.
  • the actuation chamber itself has its volume sealed such that when the fluid oxidized or is reduced, the actual volume of the chamber to change, thereby deflecting the membranes and actuating the valve.
  • the sealed actuation chamber is important in that it permits the fluid contained therein to remain free of any outside contamination,
  • the performance characteristics of the valve are defined by the dimensions of the various structures which create the valve.
  • the top membrane surface area is large with respect to the bottom membrane.
  • the top membrane is also relatively more elastic, primarily because it is thinner (of course the elasticity properties may also be varied through material selection.)
  • pressure is exerted from the chamber upon both the upper and the lower membranes.
  • the upper membrane deflects more than the bottom, thus lifting the mesa and thereby opening the valve.
  • the ratio of the surfaces of the upper and lower membranes will control the force provided through energizing the fluid contained within the outer and inner channels.
  • the thickness of the thin section in each of the upper membrane and lower membrane will define the stiffness of the springs used in the valve.
  • the thickness of the valve seat in addition, will define the pretension of such a spring, and thus the maximum pressure at which the valve remains closed with a given pressure at the inlet chamber.
  • the opening of the valve at the valve inlet chamber is equal to the deflection of the mesa minus the thickness of the valve seat. Thus this opening will control the flow fluid between the inlet and outlet channels.
  • the valve is biased in a normally closed position and the fluid pathway is blocked. This thus provides a safety feature, in that should power fail no further fluid can be delivered to the patient.
  • FIG. 3 discloses the dimensions preferred in a valve constructed according to the present invention.
  • valve which are sized differently of, indeed, configured differently may also be constructed and still be within the scope of the present invention.
  • the following sizes, moreover, are subject to the indicated tolerances.
  • FIG. 4 depicts an alternative embodiment of the present invention.
  • the valve is constructed in a less complex fashion.
  • Leaf span 51 extends between shoulders 52 and 53 and centrally features valve seat 54.
  • Valve seat covers and obstructs flow from inlet channel 61 to outlet channel 62.
  • Shoulders are mounted upon top layer 65 which is mounted, in turn, over first middle layer 66.
  • first middle layer 66 Defined between top layer and first middle layer are inlet channel 61 and outlet channel 62.
  • Inlet and outlet channels are separated by actuation nub 70.
  • actuation nub 70 has mounted atop it actuation finger 71.
  • actuation finger 71 is PyrexTM glass.
  • first middle layer 66 Positioned below first middle layer 66 is second middle layer 67 which, in turn, is positioned above bottom layer 72.
  • the second middle layer 67 is preferably glass while bottom layer is preferably silicon.
  • actuation chamber 73 is defined between first middle layer 61 and bottom layer 72 through second layer 67.
  • First middle layer features a thin deflectable span 74 positioned immediately above actuation chamber.
  • Actuation chamber is preferably filled with an electrolytic fluid such as copper sulfate, described in detail above. Chamber itself is actuated using a pair of electrodes 80 and 81, also constructed as described above.
  • valve seat 54 is polyimide.
  • FIG. 4 provides a further functionality in minimizing the risk of flow spikes during refill.
  • FIG. 5 depicts a still further embodiment of the present invention. As seen in this embodiment, all components of the valve are the same as that already described in
  • Support 100 has top plate 101 mounted thereto.
  • Bottom plate 102 is disposed opposite to top plate and is mounted to center portion 24 of upper membrane.
  • Support 100 may be either silicon or Pyrex TM glass and top and bottom plate are either gold or aluminum, although may other materials may be used of any of these components.
  • Top and bottom plates are each coupled to the control system 10 such that they may function as a capacitor. In such a manner, the degree to which the top membrane has been deflected may be determined by measuring the changes in capacitance. Knowing the pressure in the reservoir along with the degree to which the valve is opened, an accurate determination of the flow through the valve may be made.
  • a dielectric material may be disposed between each of the plates.
  • each of these components may be used in an opposite manner, that is a charge may be placed between the two plates such that electrostatic forces may be used to provide additional control to the valve, Such charge and control would also be accomplished using the control system 10.
  • FIG. 6 shows a further alternative embodiment of the present invention.
  • emergency closure device 90 is coupled to chamber 25 through electrodes 91 and 92 to provide for a relatively small energy source which will thus reverse any conditions in the electrolyte such that the valve will be permitted to close.
  • closure device comprises a small pre-charged emergency capacitor which is coupled into control system 10 (with regards to FIG. 1) and thus is able to respond to any detected system failures by closing the valve immediately.
  • a system failure may include, among other things, improper flow sensing, battery malfunction, telemetry errors as well as sudden reservoir pressure spikes.
  • FIG. 7 depicts one problem with the long term use of an electrolytic fluid.
  • the electrolyte which oxidizes in the presence of a current, will to some degree have the reaction reverse and undergo reduction. This may occur in spite of the presence of any coatings on the electrodes. Because the reduction will decrease the amount of oxygen, this will ultimately affect the pressure exerted by the fluid within the actuation chamber, and thereby affecting the degree to which the valve is opened. This is seen in FIG. 7 where at time t j the valve has reached the desired pressure Pi and the current to the electrolyte is turned off. As seen, over time the pressure exerted by the fluid within the chamber decreases, due to the reduction of the fluid.
  • FIG. 8 A One solution to the gradual reduction of the oxidized fluid is shown in FIG. 8 A.
  • the flow and thus the pressure of the fluid within the actuation chamber is sensed, preferably by a flow sensor as shown in FIG. 5.
  • a further bias current is delivered to the fluid, typically between 1-10 nanoamps , thereby reversing the reaction and stabilizing the amount of oxygen released. This therefore again increase the pressure exerted by the fluid within the actuation chamber.
  • Both the sensing operation as well as the additional current are all controlled by the electronic controls or the control system, whichever is preferred.
  • An additional solution to the gradual reduction of the oxidized fluid is shown in FIG. 8B.
  • the device senses the drop in pressure within the actuation chamber (such as by sensing flow and thereafter interpolating the actuation chamber pressure). Once the pressure decreases to a predetermined level, here shown as P 2 then energy is applied to the fluid to again initiate a reaction and cause the release of additional oxygen. Such additional energy may take the form of voltage and is applied until the desired pressure Pi is again achieved (again such as by sensing flow and thereafter interpolating the actuation chamber pressure). Thus as seen such additional energy is only intermittently applied between T 2 and T 3 for example, or subsequently between T 4 and T 5
  • FIG. 9 is a block diagram of the steps used to correct any flow variance caused by the reduction of the electrolyte.
  • the valve is actuated. This means energy, in the form of an electric current, is delivered to the fluid, at least partially oxidizing the fluid, thereby at least partially opening the valve.
  • the flow through the valve is sensed by a flow sensor. Flow sensor preferably is one such as that shown in fig. 5, although other designs may also be used.
  • the valve actuation is adjusted to reach the desired flow.
  • step 103 the flow is periodically sensed again to determine if the sensed flow rate is correspond to the desired flow rate.
  • This periodic sensing may be performed at any desired time, and preferably is programmed so as to occur at least once every hour. As discussed above, this periodic sensing is primarily to permit the device to compensate for any reduction which may occur to the oxidized fluid. Thus the specific times and frequency of the sensing will depend, in large part, to the degree to which the fluid may undergo reduction, this being a function of the fluid used, the electrode materials used, as will as the temperature and pressure of the fluid, among many other factors. As seen, if the sensed flow rate is not correspond to the desired flow rate, then the device returns to step 102 where the valve actuation is adjusted to reach the desired flow.
  • step 105 the device proceeds to step 105 and waits until the next programmed flow rate sensing is to occur, at which time it returns to step 101. In such a manner any changes to the electrolytic fluid may be periodically compensated.
  • FIG. 10 shows an alternative embodiment of the present invention.
  • a system 1 is an "active" system and includes a pump 17 to actively pump fluid from the reservoir 2, through safety valve 16 and flow regulator 7 to outlet catheter 4.
  • Flow regulator regulates the flow of material which may be transmitted from the reservoir to the outlet catheter by pump in a manner such that flow rate is independent of reservoir pressure within a given pressure range.
  • valve 16 would include a flow sensor, such a functionality may further be provided by the flow regulator, which would thus permit the flow rate to be sensed by the flow regulator.
  • Flow regulator is preferably of a design as shown in the co- pending application of Haller et al.
  • Implantable Drug Infusion Device Having a Flow Regulator (p-7322) filed this same day and incorporated herein by reference.
  • the system may be refilled through injection port 15 through the use of a needle 6 as is well known.
  • a hermetic closure 13 Surrounding all components of the implantable pump other than the outlet catheter is a hermetic closure 13 as is well known in the art.
  • Electronic controls 10, battery 11, telemetry assembly 12 and pump 17 are all constructed in any manner well known in the art. Electronic controls are powered by battery 11 and may receive remote operation instructions via telemetry assembly 12, as is well known in the art.
  • FIG. 10 is a further alternative embodiment of the present invention.
  • This embodiment provides for a less abrupt and more gradual flow should the valve fail and be left in a fully wide open position. That is, in this embodiment, even if the valve is fully wide open the flow is limited because the valve opens into and thus itself impeded fluid flow.
  • valve is constructed with an upper membrane 21, a lower membrane 22 and a substrate 23.
  • Upper and lower membranes are preferably made of silicon and substrate is preferably made of Pyrex TM glass, although other materials may also be used.
  • the areas of substrate and membranes in contact with any drug or fluid are further preferably coated with diamond or diamondlike carbon so as to inhibit any interactions between the drug or fluid and the materials.
  • Such coatings may be selected according to the particular drug or fluid to be infused, and may include also tantalum or titanium, for example.
  • upper membrane features a relatively thicker center portion 24 circumscribed by thin section 26. Thin section extends completely about center portion 24, but appears in two sections because in the preferred embodiment valve is circular.
  • Lower membrane features a relatively thicker mesa 35 circumscribed by thin section 30.
  • top and bottom membranes define between them actuation chamber 25. Extending from mesa is valve seat 40 which engages against and thereby provides a seal between inlet channel 41 and outlet channel 42.
  • Substrate 23 also features two electrodes 31, 33 which provide energy and thus actuate the electrolytic fluid within actuation chamber 25. In the preferred embodiment electrode 31 is platinum and electrode 33 is copper.
  • Electrodes may also be further coated so as to minimize any reduction of the fluid which may take place.
  • coatings may include NAFION ® available from E.I. du Pont de Nemours, Wilmington Delaware.
  • electrolytic fluid is the solution of copper sulfate, as already described above such that it will readily undergo oxidation and reduction with the electrodes.
  • the particular performance characteristics of the valve e.g. at what pressure it will open
  • the particular performance characteristics of the valve are defined by the dimensions of the various structures which create the valve.
  • this embodiment differs from those already described above in that it further feature a flow regulator disposed immediately above the mesa 24 such that valve actuation will tend to force mesa to engage against bottom surface of flow regulator 900.
  • the flow regulator essentially is a membrane having a hole 902, the membrane itself positioned above mesa such that sufficient deflection of the mesa causes the mesa to engage against the bottom layer .
  • a force is applied to the membrane, resulting in a deflection of the membrane which, in turn, impedes the flow path.
  • the bottom layer of membrane features a variable flow channel 904 such that upon mesa deflection flow may only proceed through the hole and through the flow channel.
  • FIG. 11 is a top view of a variable flow restrictor channel used in flow regulator 900.
  • FIG. 12 is a sectional view of the flow restrictor channel of FIG. 11 taken along the line 12-12.
  • the restrictor channel is essentially square in shape and has a depth roughly equal to the width.
  • other cross sectional shapes of restrictor channel may also be used, Further details of the design and operation of such a flow regulator may be found in the above referenced United States patent application entitled "Implantable Drug Infusion Device Having A Flow Regulator" of Markus Haller, Phillipe Renaud and Christian Amacker (Our File: P- 7322 (Including P-7353)).

Landscapes

  • Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

The present invention features a valve (3) constructed using an electrolytic fluid, the fluid releasing a gas when subject to an electronic current, the same gas absorbed again by the fluid when such current is removed. The fluid is housed within an actuation chamber (25) such that the out-gassing of the fluid deforms the membranes (21, 22, 23) defining the chamber. The membranes (21, 22, 23) are positioned such that this deformation will inhibit or completely restrict the flow pathway (41, 42) between the reservoir and the patient. Through such a design a valve is provided which has complete variability in the possible flow rates but which uses a minimal amount of electronic current. The valve has the safety feature of being in the normally closed position when no energy is provided.

Description

IMPLANTABLE DRUG INFUSION DEVICE
HAVING AN IMPROVED VALVE
RELATED APPLICATIONS This application is related to one or more of the following each of which are filed on this same day, each incorporated herein by reference and each assigned to the assignee of the present application:
- United States patent application entitled "System For Locating Implantable Medical Device" of Markus Haller and Koen Weijand (Our File: P-7521); - United States patent application entitled "Implantable Drug Infusion Device
Having A Flow Regulator" of Markus Haller, Phillipe Renaud and Christian Amacker (Our File: P-7322 (Including P-7353)); and
- United States patent application entitled "Implantable Drug Infusion Device Having A Safety Valve" of Markus Haller and Koen Weijand (Our File: P-7354 (including P-7329)).
FIELD OF THE INVENTION
The present invention relates to the field of implantable drug infusion devices and more particularly to an implantable drug infusion device having a low power multi-stable valve capable of providing a range of flow therethrough.
BACKGROUND OF THE INVENTION
Implantable are used to provide patients with a constant or programmable dosage or infusion of a drug or any other therapeutic agent. An example of such an implantable drug infusion device currently available is the Medtronic SynchroMed drug pump. Such a device includes a drug reservoir, a peristaltic pump to pump out the drug from the reservoir and a catheter port to transport the pumped out drug from the reservoir via the pump and into the patient. Typically, the drug is provided into the reservoir at a very low pressure and the drug must therefore be forced out of the reservoir and into the patient by a pump. This device requires a battery to power the pump as well as an electronic module to control the pump. Needless to say, because a separate pump battery and electronic module is required, the cost of this device is greater than desired.
An alternative design to an active pumping implantable medical device are devices which do not require the use of a separate pump, but instead rely upon a pressurized reservoir to deliver the drug. An example of such a device includes the Medtronic IsoMed™. The presently available device, however, although requiring low power, does not provide the optimal therapy to the patient. In particular, all such devices currently available feature valves to control the flow of the drug which may only be in a fully open or fully closed position, for example, they are not able to be opened only half-way. The consequences of such a limited option for valve control is that the flow rate of the drug provided to the patient is either completely on or completely off. This causes, not surprisingly, the amount of drug in the patient's blood stream to also vary in a similar fashion, tending to oscillate between a peak and a valley in phase with the opening and closing of the valve. Moreover such valves, besides providing less than optimal drug delivery to the patient, also require a larger amount of energy than is desired. As such, there exists a need for a low power valve which may be used in an implantable medical pump and which provides complete variability in the flow rate through the valve.
SUMMARY OF THE INVENTION
These and several other problems are solved by the present invention which provides an implantable medical pump featuring a low power multi-stable valve. In particular, the present invention features a valve constructed using an electrolytic fluid, the fluid releasing a gas when subject to an electronic current, the same gas absorbed again by the fluid when such current is removed. The fluid is further housed within an uniquely designed actuation chamber such that the out-gassing of the fluid deforms the membranes defining the chamber. The membranes, in turn, are positioned such that this deformation will inhibit or completely restrict the flow pathway between the reservoir and ultimately the patient. Through such a design a valve is provided which has complete variability in the possible flow rates but which uses a minimal amount of electronic current. Moreover, the valve has the additional safety feature of being in the normally closed position when no energy is provided. In a further embodiment the pump features such a valve coupled to a flow sensor, the flow sensor thereby providing input to control the electrolytic fluid and thereby the valve position. A still further embodiment provides a method of compensating for any changes in the electrolytic fluid over time caused by reduction or oxidation of the fluid. Such compensation is provided through the application of a biasing current to thereby inhibit any such reduction or oxidation of the fluid.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a block diagram of the present invention.
FIGS. 2 A and 2B are side views of a low power multi-stable valve used in the present invention, where in FIG 2A the valve is closed and in FIG. 2B the valve is opened.
FIG. 3 discloses the dimensions preferred in a valve constructed according to the present invention.
FIG. 4 depicts an alternative embodiment of the present invention.
FIG. 5 depicts a still further embodiment of the present invention. FIG. 6 shows a further alternative embodiment of the present invention.
FIG. 7 depicts one problem with the long term use of an electrolytic fluid.
FIGS. 8 A and B depict solutions to the problem illustrated in FIG. 7
FIG. 9 is a block diagram of the steps used to correct any flow variance caused by the reduction of the electrolyte. FIG. 10 shows an alternative embodiment of the present invention featuring a flow regulator.
FIG. 11 is a top view of a variable flow restrictor channel used in flow regulator.
FIG. 12 is a sectional view of the flow restrictor channel of FIG. 11 taken along the line 12-12 The FIGS, are not necessarily to scale.
DETAILED DESCRIPTION OF THE DRAWINGS
FIG. 1 is a block diagram of the present invention. As seen, such a system 1 comprises a reservoir 2, valve 3, flow sensor 4, electronic controls 10, battery 11, telemetry assembly 12 and outlet catheter 5. Valve 3 is coupled to the reservoir and also to flow sensor 4. Flow sensor 4 is coupled, in turn to outlet catheter 5, such that fluid form reservoir 2 may be pumped through valve and out to outlet catheter. Outlet catheter may be of any model desired and suited to the patient's requirements. Flow sensor is controlled by electronic controls 10. These controls include, among other devices, an efficient circuit to drive the actuators used in valve 3. The device may be refilled through injection port 5 through the use of a needle 6 as is well known. This refill procedure may be furtehr enhanced through the use of the system as described in the above referenced United States patent application entitled "System For Locating Implantable Medical Device" of Markus Haller and Koen Weijand (Our File: P-
7521). Surrounding all components of the implantable flow sensor other than the outlet catheter is a hermetic closure 13 as is well known in the art.
FIGS. 2A and 2B are side views of a low power multi-stable valve used in the present invention. The valve is shown in FIG. 2A in the closed position and in FIG. 2B in the open position. As seen valve is constructed with an upper membrane 21, a lower membrane 22 and a substrate 23. Upper and lower membranes are preferably made of silicon and substrate is preferably made of Pyrex ™ glass, although other materials may also be used. Moreover, the areas of substrate and membranes in contact with any drug or fluid are further preferably coated with diamond or diamond-like carbon so as to inhibit any interactions between the drug or fluid and the materials. Such coatings may be selected according to the particular drug or fluid to be infused, and may include also tantalum or titanium, for example
As seen, upper membrane features a relatively thicker center portion 24 circumscribed by thin section 26. Thin section extends completely about center portion 24, but appears in two sections because in the preferred embodiment valve is circular. Lower membrane features a relatively thicker mesa 35 circumscribed by thin section 30. As seen top and bottom membranes define between them actuation chamber 25. Extending from mesa is valve seat 40 which engages against and thereby provides a seal between inlet channel 41 and outlet channel 42. Substrate 23 also features two electrodes 31, 33 which provide energy to the electrolytic fluid within actuation chamber 25, causing it to either undergo reduction or oxidation and thus actuate the valve. In the preferred embodiment electrode 31 is platinum and electrode 33 is copper. Electrodes may also be further coated so as to minimize any reduction of the fluid which may take place. Such coatings may include NAFION available from E.I. du Pont de Nemours, Wilmington Delaware. In the preferred embodiment electrolytic fluid is a solution of copper sulfate, such that it will readily undergo oxidation and reduction with the electrodes. The reversible reactions used to electrochemically actuate the valve are given by:
2H2O(l) O2(g) + 4H+(aq) + 4e E =1.23V
Cu2+ (aq) + 2e » Cu(s) E°=0.34V
which gives:
2H2O(l) + Cu2+ (aq) o O2(g) + 4H+ (aq) + Cu(s) E°=0.89V
To open the valve, in one embodiment for example, 10 μm a pressure increase of 200 mbar is required to be applied. A deflection of the membrane of 10 μm will increase the volume in the actuation chamber of about 2.5 μl. This volume has to be created by the production of O2 by electrolyze of the electrolyte. A pressure of 200 mbar will result in a decrease in molecular volume from 24.51/mol to 20.41/mol. To make 2.5 μl you will need around 1.25'10"10mol O2 and thus 5 10"10 mol electrons. To get this deflection in 10 seconds, you will need a current of I=Q/t = Fn/t=(9.65 1045 10"10)/10=4.8μA. To supply this current a voltage has to be applied over the electrodes and the electrolyte. Using electrodes of 500x500 μm and an electrolyte of 0.5M H2SO4 mixed with 0.5M CuSO4, the required supply voltage will be around 2 Volts. Further details concerning such a system may be found in Neagu et al., "Electrochemical Microvalve", Proceedings 1996
National Sensor Conference, Delft, The Netherlands, March 20-21, 1996, ISBN 90-407-1321-9 / CIP, incorporated herein by reference.
FIG. 2B which depicts the valve 3 opened. As seen, the electrolyte positioned within actuation chamber 25 has been energized, i.e., a small amount of electricity, typically less than 2 Volts has been supplied over a sufficient time to oxidize the fluid, thereby releasing gaseous oxygen which in turn causes the membranes to deflect and thus actuate the valve. Of course, the exact amount of electricity required depends in part upon the size of the electrodes used such that a sufficient current density is achieved. As can be understood, the actuation chamber itself has its volume sealed such that when the fluid oxidized or is reduced, the actual volume of the chamber to change, thereby deflecting the membranes and actuating the valve. The sealed actuation chamber is important in that it permits the fluid contained therein to remain free of any outside contamination, thus ensuring reliable valve operation, an essential characteristic for any implantable device.
The performance characteristics of the valve (e.g. at what pressure it will open) are defined by the dimensions of the various structures which create the valve. In the preferred embodiment the top membrane surface area is large with respect to the bottom membrane. The top membrane is also relatively more elastic, primarily because it is thinner (of course the elasticity properties may also be varied through material selection.) Upon actuation, that is increase in the pressure within the chamber (caused by the partial oxidation of the fluid), pressure is exerted from the chamber upon both the upper and the lower membranes. The upper membrane, however, deflects more than the bottom, thus lifting the mesa and thereby opening the valve. Thus it is critical to the operation of the present invention that these various structure be sized correctly. For instance, the ratio of the surfaces of the upper and lower membranes will control the force provided through energizing the fluid contained within the outer and inner channels. Moreover, the thickness of the thin section in each of the upper membrane and lower membrane will define the stiffness of the springs used in the valve. The thickness of the valve seat, in addition, will define the pretension of such a spring, and thus the maximum pressure at which the valve remains closed with a given pressure at the inlet chamber. As can be appreciated, the opening of the valve at the valve inlet chamber is equal to the deflection of the mesa minus the thickness of the valve seat. Thus this opening will control the flow fluid between the inlet and outlet channels. Finally, as seen, in the preferred embodiment the valve is biased in a normally closed position and the fluid pathway is blocked. This thus provides a safety feature, in that should power fail no further fluid can be delivered to the patient.
FIG. 3 discloses the dimensions preferred in a valve constructed according to the present invention. Of course valve which are sized differently of, indeed, configured differently may also be constructed and still be within the scope of the present invention. The following sizes, moreover, are subject to the indicated tolerances.
Figure imgf000009_0001
Figure imgf000010_0001
FIG. 4 depicts an alternative embodiment of the present invention. As seen, in this embodiment the valve is constructed in a less complex fashion. Leaf span 51 extends between shoulders 52 and 53 and centrally features valve seat 54. Valve seat covers and obstructs flow from inlet channel 61 to outlet channel 62. Shoulders are mounted upon top layer 65 which is mounted, in turn, over first middle layer 66. Defined between top layer and first middle layer are inlet channel 61 and outlet channel 62. Inlet and outlet channels are separated by actuation nub 70. As seen, actuation nub 70 has mounted atop it actuation finger 71. In this embodiment, actuation finger 71 is Pyrex™ glass. Positioned below first middle layer 66 is second middle layer 67 which, in turn, is positioned above bottom layer 72. The second middle layer 67 is preferably glass while bottom layer is preferably silicon. As seen, actuation chamber 73 is defined between first middle layer 61 and bottom layer 72 through second layer 67. First middle layer features a thin deflectable span 74 positioned immediately above actuation chamber. Actuation chamber is preferably filled with an electrolytic fluid such as copper sulfate, described in detail above. Chamber itself is actuated using a pair of electrodes 80 and 81, also constructed as described above. In such a manner, the electrolytic fluid in chamber 73 may be caused to oxidizes, thereby releasing gaseous oxygen, which increases the pressure within chamber and thus deflects span 74 upwards. This, in turn forces 70 and thus 71 upwards thereby moving valve seat 54 upwards and thus opening a flow path between inlet chamber 61 and outlet chamber 62. In the preferred embodiment valve seat 54 is polyimide. As can be appreciated in this view, because the span 51 and thus valve seat 54 is disposed in opposition to the pressure of the pressurized reservoir, sudden flow pressure conditions, such as during refill, will force the valve to close or, at the very least, impede further flow through the valve. Thus the embodiment shown in FIG. 4 provides a further functionality in minimizing the risk of flow spikes during refill.
FIG. 5 depicts a still further embodiment of the present invention. As seen in this embodiment, all components of the valve are the same as that already described in
FIGS. 2A and 2B, except for the following additional components. Support 100 has top plate 101 mounted thereto. Bottom plate 102 is disposed opposite to top plate and is mounted to center portion 24 of upper membrane. Support 100 may be either silicon or Pyrex ™ glass and top and bottom plate are either gold or aluminum, although may other materials may be used of any of these components. Top and bottom plates are each coupled to the control system 10 such that they may function as a capacitor. In such a manner, the degree to which the top membrane has been deflected may be determined by measuring the changes in capacitance. Knowing the pressure in the reservoir along with the degree to which the valve is opened, an accurate determination of the flow through the valve may be made. As additional component, a dielectric material may be disposed between each of the plates. Also, each of these components may be used in an opposite manner, that is a charge may be placed between the two plates such that electrostatic forces may be used to provide additional control to the valve, Such charge and control would also be accomplished using the control system 10.
FIG. 6 shows a further alternative embodiment of the present invention. As seen in this embodiment, all elements of the valve are the same as that described above with regards to FIGS. 2 A and 2B, but for the additional incorporation of emergency closure device 90. As seen, emergency closure device 90 is coupled to chamber 25 through electrodes 91 and 92 to provide for a relatively small energy source which will thus reverse any conditions in the electrolyte such that the valve will be permitted to close. In one embodiment closure device comprises a small pre-charged emergency capacitor which is coupled into control system 10 (with regards to FIG. 1) and thus is able to respond to any detected system failures by closing the valve immediately. Such a system failure may include, among other things, improper flow sensing, battery malfunction, telemetry errors as well as sudden reservoir pressure spikes.
FIG. 7 depicts one problem with the long term use of an electrolytic fluid. In particular, over time the electrolyte, which oxidizes in the presence of a current, will to some degree have the reaction reverse and undergo reduction. This may occur in spite of the presence of any coatings on the electrodes. Because the reduction will decrease the amount of oxygen, this will ultimately affect the pressure exerted by the fluid within the actuation chamber, and thereby affecting the degree to which the valve is opened. This is seen in FIG. 7 where at time tj the valve has reached the desired pressure Pi and the current to the electrolyte is turned off. As seen, over time the pressure exerted by the fluid within the chamber decreases, due to the reduction of the fluid.
One solution to the gradual reduction of the oxidized fluid is shown in FIG. 8 A. As seen, in this system, the flow and thus the pressure of the fluid within the actuation chamber is sensed, preferably by a flow sensor as shown in FIG. 5. As seen at Tj, once flow is sensed, essentially indicating a pressure P2 is present, a further bias current is delivered to the fluid, typically between 1-10 nanoamps , thereby reversing the reaction and stabilizing the amount of oxygen released. This therefore again increase the pressure exerted by the fluid within the actuation chamber. Both the sensing operation as well as the additional current are all controlled by the electronic controls or the control system, whichever is preferred. An additional solution to the gradual reduction of the oxidized fluid is shown in FIG. 8B. As seen, in this system, rather than the continuos application of a current to the fluid to thus bias the reaction, the device senses the drop in pressure within the actuation chamber (such as by sensing flow and thereafter interpolating the actuation chamber pressure). Once the pressure decreases to a predetermined level, here shown as P2 then energy is applied to the fluid to again initiate a reaction and cause the release of additional oxygen. Such additional energy may take the form of voltage and is applied until the desired pressure Pi is again achieved (again such as by sensing flow and thereafter interpolating the actuation chamber pressure). Thus as seen such additional energy is only intermittently applied between T2 and T3 for example, or subsequently between T4 and T5
FIG. 9 is a block diagram of the steps used to correct any flow variance caused by the reduction of the electrolyte. As seen in step 100 the valve is actuated. This means energy, in the form of an electric current, is delivered to the fluid, at least partially oxidizing the fluid, thereby at least partially opening the valve. Next at step 101 the flow through the valve is sensed by a flow sensor. Flow sensor preferably is one such as that shown in fig. 5, although other designs may also be used. Next at step 102 the valve actuation is adjusted to reach the desired flow. Next at step 103 , the flow is periodically sensed again to determine if the sensed flow rate is correspond to the desired flow rate. This periodic sensing may be performed at any desired time, and preferably is programmed so as to occur at least once every hour. As discussed above, this periodic sensing is primarily to permit the device to compensate for any reduction which may occur to the oxidized fluid. Thus the specific times and frequency of the sensing will depend, in large part, to the degree to which the fluid may undergo reduction, this being a function of the fluid used, the electrode materials used, as will as the temperature and pressure of the fluid, among many other factors. As seen, if the sensed flow rate is not correspond to the desired flow rate, then the device returns to step 102 where the valve actuation is adjusted to reach the desired flow. Otherwise, if the sensed flow rate is correspond to the desired flow rate, then the device proceeds to step 105 and waits until the next programmed flow rate sensing is to occur, at which time it returns to step 101. In such a manner any changes to the electrolytic fluid may be periodically compensated.
FIG. 10 shows an alternative embodiment of the present invention. As seen, such a system 1 is an "active" system and includes a pump 17 to actively pump fluid from the reservoir 2, through safety valve 16 and flow regulator 7 to outlet catheter 4. Flow regulator regulates the flow of material which may be transmitted from the reservoir to the outlet catheter by pump in a manner such that flow rate is independent of reservoir pressure within a given pressure range. Although in this embodiment valve 16 would include a flow sensor, such a functionality may further be provided by the flow regulator, which would thus permit the flow rate to be sensed by the flow regulator. Flow regulator is preferably of a design as shown in the co- pending application of Haller et al. "Implantable Drug Infusion Device Having a Flow Regulator" (p-7322) filed this same day and incorporated herein by reference. As already described above, the system may be refilled through injection port 15 through the use of a needle 6 as is well known. Surrounding all components of the implantable pump other than the outlet catheter is a hermetic closure 13 as is well known in the art. Electronic controls 10, battery 11, telemetry assembly 12 and pump 17 are all constructed in any manner well known in the art. Electronic controls are powered by battery 11 and may receive remote operation instructions via telemetry assembly 12, as is well known in the art.
FIG. 10 is a further alternative embodiment of the present invention. This embodiment provides for a less abrupt and more gradual flow should the valve fail and be left in a fully wide open position. That is, in this embodiment, even if the valve is fully wide open the flow is limited because the valve opens into and thus itself impeded fluid flow. As seen valve is constructed with an upper membrane 21, a lower membrane 22 and a substrate 23. Upper and lower membranes are preferably made of silicon and substrate is preferably made of Pyrex ™ glass, although other materials may also be used. Moreover, the areas of substrate and membranes in contact with any drug or fluid are further preferably coated with diamond or diamondlike carbon so as to inhibit any interactions between the drug or fluid and the materials. Such coatings may be selected according to the particular drug or fluid to be infused, and may include also tantalum or titanium, for example. As seen, upper membrane features a relatively thicker center portion 24 circumscribed by thin section 26. Thin section extends completely about center portion 24, but appears in two sections because in the preferred embodiment valve is circular. Lower membrane features a relatively thicker mesa 35 circumscribed by thin section 30. As seen top and bottom membranes define between them actuation chamber 25. Extending from mesa is valve seat 40 which engages against and thereby provides a seal between inlet channel 41 and outlet channel 42. Substrate 23 also features two electrodes 31, 33 which provide energy and thus actuate the electrolytic fluid within actuation chamber 25. In the preferred embodiment electrode 31 is platinum and electrode 33 is copper. Electrodes may also be further coated so as to minimize any reduction of the fluid which may take place. Such coatings may include NAFION® available from E.I. du Pont de Nemours, Wilmington Delaware. In the preferred embodiment electrolytic fluid is the solution of copper sulfate, as already described above such that it will readily undergo oxidation and reduction with the electrodes. As already discussed above the particular performance characteristics of the valve (e.g. at what pressure it will open) are defined by the dimensions of the various structures which create the valve. As seen this embodiment differs from those already described above in that it further feature a flow regulator disposed immediately above the mesa 24 such that valve actuation will tend to force mesa to engage against bottom surface of flow regulator 900. The flow regulator essentially is a membrane having a hole 902, the membrane itself positioned above mesa such that sufficient deflection of the mesa causes the mesa to engage against the bottom layer . As liquid flows through the hole a force is applied to the membrane, resulting in a deflection of the membrane which, in turn, impedes the flow path. The bottom layer of membrane features a variable flow channel 904 such that upon mesa deflection flow may only proceed through the hole and through the flow channel. By tailoring the shape and length of the variable flow channel the flow characteristics of the regulator versus pressure may be adjusted.
FIG. 11 is a top view of a variable flow restrictor channel used in flow regulator 900. As seen in this embodiment, restrictor channel is essentially spiral shaped according to the following equation: a ■ cost , a • sint x = and v = for -co < t < 0 and 0 < t < ∞ t t where "a" is 1 in the preferred embodiment, although any value between approximately 0.1 to 100 may also be chosen
FIG. 12 is a sectional view of the flow restrictor channel of FIG. 11 taken along the line 12-12. As seen in this embodiment, the restrictor channel is essentially square in shape and has a depth roughly equal to the width. Of course, other cross sectional shapes of restrictor channel may also be used, Further details of the design and operation of such a flow regulator may be found in the above referenced United States patent application entitled "Implantable Drug Infusion Device Having A Flow Regulator" of Markus Haller, Phillipe Renaud and Christian Amacker (Our File: P- 7322 (Including P-7353)). Although various embodiments of the invention have been disclosed, this is done for purposes of illustration and is not intended to be limiting with regard to the scope of the invention. It is contemplated various substitutions, alterations and/or modifications may be made to the disclosed embodiment without departing from the spirit and scope of the invention. Such modifications may include substituting elements or components which perform substantially the same function in substantially the same way to achieve substantially the same result for those described herein.

Claims

What is claimed is:
1. An implantable drug infusion device comprising: a hermetic enclosure; a fluid reservoir positioned within the hermetic enclosure, the fluid reservoir having an fluid outlet port; means for delivering a fluid into a patient's body, the delivering means in fluid communication with the fluid reservoir; and valve means for controlling the flow of fluid from the reservoir to the means for delivering a fluid into a patient's body, the valve means having a sealed actuation chamber.
2. An implantable drug infusion device according to claim 1 further comprising means for selectively altering the sealed actuation chamber volume between a first volume and a second volume.
3. An implantable drug infusion device according to claim 1 wherein the means for selectively altering the sealed actuation chamber volume between a first volume and a second volume comprise an electrolytic fluid contained within the sealed actuation chamber.
4. An implantable drug infusion device according to claim 3 further comprising control means coupled to the means for selectively oxidizing or reducing the electrolytic fluid contained in the sealed actuation chamber, the control means controlling the degree of oxidation or reduction.
5. An implantable drug infusion device according to claim 1 wherein the valve means comprise means for selectively oxidizing or reducing the electrolytic fluid contained in the sealed actuation chamber.
6. An implantable drug infusion device according to claim 5 wherein the means for selectively oxidizing or reducing the electrolytic fluid contained in the sealed actuation chamber comprise a first electrode and a second electrode.
7. An implantable drug infusion device according to claim 1 wherein the valve is biased in a normally closed position and the fluid pathway is blocked.
8. An implantable drug infusion device according to claim 1 further comprising a the surfaces of the valve in contact with the fluid have a coating of diamond or diamond-like carbon whereby interactions between the fluid and the materials are inhibited..
9. An implantable drug infusion device according to claim 1 wherein the valve means comprises an upper membrane, a lower membrane and a substrate, upper membrane features a relatively thicker center portion circumscribed by thin section, lower membrane features a relatively thicker mesa circumscribed by thin section, the top and bottom membranes define therebetween the sealed actuation chamber, the upper and lower membrane cooperating to bias the valve is biased in a normally closed position and block the fluid pathway.
10. An implantable drug infusion device comprising: a hermetic enclosure; a fluid reservoir positioned within the hermetic enclosure, the fluid reservoir having an fluid outlet port; means for delivering a fluid into a patient's body, the delivering means in fluid communication with the fluid reservoir; and valve means for controlling the flow of fluid from the reservoir to the means for delivering a fluid into a patient's body, the valve means having a sealed actuation chamber, an electrolytic fluid contained within the sealed actuation chamber. means for actuating the valve open; means for sensing flow through the valve; means for adjusting the means for actuating the valve open to reach the desired flow.
11. An implantable drug infusion device according to claim 10 further comprising means for sensing whether sensed flow rate correspond to the desired flow rate
12. An implantable drug infusion device according to claim 10 further comprising means for selectively altering the sealed actuation chamber volume between a first volume and a second volume.
13. An implantable drug infusion device according to claim 12 wherein the means for selectively altering the sealed actuation chamber volume between a first volume and a second volume comprise means for selectively oxidizing or reducing the electrolytic fluid contained in the sealed actuation chamber.
14. An implantable drug infusion device according to claim 11 further comprising control means coupled to the means for selectively oxidizing or reducing the electrolytic fluid contained in the sealed actuation chamber, the control means controlling the degree of oxidation or reduction.
15. An implantable drug infusion device according to claim 10 further comprising a the surfaces of the valve in contact with the fluid have a coating of diamond or diamond-like carbon whereby interactions between the fluid and the materials are inhibited..
16. An implantable drug infusion device comprising: a hermetic enclosure; a fluid reservoir positioned within the hermetic enclosure, the fluid reservoir having an fluid outlet port; means for delivering a fluid into a patient's body, the delivering means in fluid communication with the fluid reservoir; and valve means for controlling the flow of fluid from the reservoir to the means for delivering a fluid into a patient's body, the valve means having a sealed actuation chamber the valve is biased in a normally closed position and the fluid pathway is blocked.
17. An implantable drug infusion device according to claim 16 further comprising means for selectively altering the sealed actuation chamber volume between a first volume and a second volume.
18. An implantable drug infusion device according to claim 16 wherein the means for selectively altering the sealed actuation chamber volume between a first volume and a second volume comprise an electrolytic fluid contained within the sealed actuation chamber.
19. An implantable drug infusion device according to claim 18 further comprising control means coupled to the means for selectively oxidizing or reducing the electrolytic fluid contained in the sealed actuation chamber , the control means controlling the degree of oxidation or reduction.
20. An implantable drug infusion device according to claim 16 wherein the valve means comprise means for selectively oxidizing or reducing the electrolytic fluid contained in the sealed actuation chamber.
21. An implantable drug infusion device according to claim 20 wherein the means for selectively oxidizing or reducing the electrolytic fluid contained in the sealed actuation chamber comprise a first electrode and a second electrode.
22. An implantable drug infusion device according to claim 16 further comprising a coating of diamond or diamond-like carbon on the surfaces of the valve in contact with the fluid a whereby interactions between the fluid and the materials are inhibited..
23. An implantable drug infusion device according to claim 16 wherein the valve means comprises an upper membrane, a lower membrane and a substrate, upper membrane features a relatively thicker center portion circumscribed by thin section, lower membrane features a relatively thicker mesa circumscribed by thin section, the top and bottom membranes define therebetween the sealed actuation chamber.
24. An implantable drug infusion device according to claim 16 further comprising electrolytic fluid within the sealed actuation chamber.
25. An implantable drug infusion device according to claim 23 wherein the substrate features at least one electrode which provides energy and thus actuate the electrolytic fluid within sealed actuation chamber
26. An implantable drug infusion device according to claim 25 electrodes further having means for minimizing any reduction of the fluid which may take place
27. An implantable drug infusion device according to claim 26 wherein the means
(S) for minimizing. NAFION
28. An implantable drug infusion device according to claim 25 wherein the electrode is platinum
29. An implantable drug infusion device according to claim 23 wherein the upper and the lower membranes are made of silicon and the substrate is preferably made of glass,
30. An implantable drug infusion device according to claim 19 further comprising means for minimizing the gradual reduction of the electrolytic fluid after it has been oxidized, the minimizing means comprising sensing flow of fluid through the value and applying additional energy to the electrolytic fluid until the sensed flow is stopped.
PCT/US1999/002172 1998-02-02 1999-02-01 Implantable drug infusion device having an improved valve WO1999038553A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP99905609A EP1053036B1 (en) 1998-02-02 1999-02-01 Implantable drug infusion device having an improved valve
AU25734/99A AU2573499A (en) 1998-02-02 1999-02-01 Implantable drug infusion device having an improved valve
DE69902145T DE69902145T2 (en) 1998-02-02 1999-02-01 IMPLANTABLE INFUSION DEVICE WITH IMPROVED VALVE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/017,196 1998-02-02
US09/017,196 US6048328A (en) 1998-02-02 1998-02-02 Implantable drug infusion device having an improved valve

Publications (2)

Publication Number Publication Date
WO1999038553A1 true WO1999038553A1 (en) 1999-08-05
WO1999038553A9 WO1999038553A9 (en) 1999-10-21

Family

ID=21781262

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/002172 WO1999038553A1 (en) 1998-02-02 1999-02-01 Implantable drug infusion device having an improved valve

Country Status (5)

Country Link
US (1) US6048328A (en)
EP (1) EP1053036B1 (en)
AU (1) AU2573499A (en)
DE (1) DE69902145T2 (en)
WO (1) WO1999038553A1 (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018089A1 (en) * 2001-08-31 2003-03-06 Institute Of Materials Research And Engineering Liquid delivering device
WO2005044342A1 (en) * 2003-11-07 2005-05-19 Agency For Science, Technology And Research Liquid housing chamber and liquid delivering device containing such chamber
WO2009053914A1 (en) * 2007-10-25 2009-04-30 Koninklijke Philips Electronics N.V. Implantable drug delivery system
US8382723B2 (en) 2005-03-04 2013-02-26 C. R. Bard, Inc. Access port identification systems and methods
US8382724B2 (en) 2005-03-04 2013-02-26 C. R. Bard, Inc. Systems and methods for radiographically identifying an access port
USD676955S1 (en) 2010-12-30 2013-02-26 C. R. Bard, Inc. Implantable access port
USD682416S1 (en) 2010-12-30 2013-05-14 C. R. Bard, Inc. Implantable access port
US8475417B2 (en) 2005-04-27 2013-07-02 C. R. Bard, Inc. Assemblies for identifying a power injectable access port
US8608713B2 (en) 1998-12-07 2013-12-17 C. R. Bard, Inc. Septum feature for identification of an access port
US8641676B2 (en) 2005-04-27 2014-02-04 C. R. Bard, Inc. Infusion apparatuses and methods of use
US8932271B2 (en) 2008-11-13 2015-01-13 C. R. Bard, Inc. Implantable medical devices including septum-based indicators
US8998860B2 (en) 2005-03-04 2015-04-07 C. R. Bard, Inc. Systems and methods for identifying an access port
US9079004B2 (en) 2009-11-17 2015-07-14 C. R. Bard, Inc. Overmolded access port including anchoring and identification features
US9265912B2 (en) 2006-11-08 2016-02-23 C. R. Bard, Inc. Indicia informative of characteristics of insertable medical devices
US9474888B2 (en) 2005-03-04 2016-10-25 C. R. Bard, Inc. Implantable access port including a sandwiched radiopaque insert
US9579496B2 (en) 2007-11-07 2017-02-28 C. R. Bard, Inc. Radiopaque and septum-based indicators for a multi-lumen implantable port
US9603993B2 (en) 2005-03-04 2017-03-28 C. R. Bard, Inc. Access port identification systems and methods
US9642986B2 (en) 2006-11-08 2017-05-09 C. R. Bard, Inc. Resource information key for an insertable medical device
US10307581B2 (en) 2005-04-27 2019-06-04 C. R. Bard, Inc. Reinforced septum for an implantable medical device
WO2021110801A1 (en) 2019-12-06 2021-06-10 Sanofi Dosing mechanism with rotational end stop mechanism for terminating dose dispense
US11890443B2 (en) 2008-11-13 2024-02-06 C. R. Bard, Inc. Implantable medical devices including septum-based indicators

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6485462B1 (en) 1997-08-27 2002-11-26 Science Incorporated Fluid delivery device with heat activated energy source
US20030036746A1 (en) * 2001-08-16 2003-02-20 Avi Penner Devices for intrabody delivery of molecules and systems and methods utilizing same
US7070577B1 (en) * 1998-02-02 2006-07-04 Medtronic, Inc Drive circuit having improved energy efficiency for implantable beneficial agent infusion or delivery device
EP1058565B1 (en) * 1998-02-02 2003-05-02 Medtronic, Inc. Implantable drug infusion device having a safety valve
US6554822B1 (en) 1999-04-30 2003-04-29 University Of Southern California Microbolus infusion pump
CA2370623C (en) * 1999-06-08 2004-07-20 Medical Research Group, Inc. Method and apparatus for infusing liquids using a chemical reaction in an implanted infusion device
US6589205B1 (en) * 1999-12-17 2003-07-08 Advanced Bionica Corporation Externally-controllable constant-flow medication delivery system
US6764472B1 (en) 2000-01-11 2004-07-20 Bard Access Systems, Inc. Implantable refillable infusion device
US6769626B1 (en) 2000-10-30 2004-08-03 Instrumentarium Corp. Device and method for detecting and controlling liquid supply to an apparatus discharging liquids
ES2574917T3 (en) 2000-11-30 2016-06-23 Valeritas, Inc. Fluid supply and measurement systems and procedures
US7776029B2 (en) 2001-01-30 2010-08-17 The Alfred E. Mann Foundation For Scientific Research Microminiature infusion pump
DE10151471A1 (en) * 2001-10-18 2003-05-15 Disetronic Licensing Ag Injection device with energy storage
US6842642B2 (en) 2001-11-09 2005-01-11 Medtronic, Inc. Adjustable cardiac resynchronization
US20040073175A1 (en) * 2002-01-07 2004-04-15 Jacobson James D. Infusion system
GB2403421B (en) * 2002-04-08 2005-07-13 Rosemount Inc Implantable pressure-activated micro-valve
US6976590B2 (en) 2002-06-24 2005-12-20 Cytonome, Inc. Method and apparatus for sorting particles
US6877528B2 (en) * 2002-04-17 2005-04-12 Cytonome, Inc. Microfluidic system including a bubble valve for regulating fluid flow through a microchannel
US9943847B2 (en) 2002-04-17 2018-04-17 Cytonome/St, Llc Microfluidic system including a bubble valve for regulating fluid flow through a microchannel
US6808075B2 (en) 2002-04-17 2004-10-26 Cytonome, Inc. Method and apparatus for sorting particles
US7527608B2 (en) * 2002-08-12 2009-05-05 Lma North America, Inc. Medication infusion and aspiration system and method
US7150741B2 (en) * 2002-09-20 2006-12-19 Advanced Neuromodulation Systems, Inc. Programmable dose control module
US6957655B2 (en) 2002-09-20 2005-10-25 Advanced Neuromodulation Systems, Inc. Apparatus for dosage control
US7162308B2 (en) * 2002-11-26 2007-01-09 Wilson Greatbatch Technologies, Inc. Nanotube coatings for implantable electrodes
US7559926B1 (en) 2003-01-13 2009-07-14 Advanced Neuromodulation Systems, Inc. Actuation system and method for an implantable infusion pump
EP1622592A4 (en) * 2003-03-27 2008-09-17 Medical Res Products A Inc Implantable medication delivery device using pressure regulator
US7186247B2 (en) * 2003-04-04 2007-03-06 Medtronic, Inc. Apparatus and system for delivery of drug therapies
JP4565193B2 (en) 2003-04-23 2010-10-20 バレリタス， インコーポレイテッド Hydraulically operated pump for long duration pharmaceutical administration
WO2004098390A2 (en) * 2003-04-30 2004-11-18 Insulet Corporation Rf medical device
WO2005007223A2 (en) * 2003-07-16 2005-01-27 Sasha John Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations
US7367968B2 (en) * 2003-09-05 2008-05-06 Codman & Shurtleff, Inc. Implantable pump with adjustable flow rate
US20050187515A1 (en) * 2004-02-19 2005-08-25 Advanced Neuromodulation Systems, Inc. Reduced size programmable drug pump
WO2006014425A1 (en) 2004-07-02 2006-02-09 Biovalve Technologies, Inc. Methods and devices for delivering glp-1 and uses thereof
US7437644B2 (en) * 2004-10-29 2008-10-14 Codman Neuro Sciences Sárl Automatic self-testing of an internal device in a closed system
US8100889B2 (en) * 2004-11-10 2012-01-24 Olympus Corporation Body-insertable apparatus
JP4823510B2 (en) * 2004-11-10 2011-11-24 オリンパス株式会社 Intra-subject introduction device
CA2791286C (en) * 2004-11-22 2015-09-01 Intelliject, Inc. Devices, systems, and methods for medicament delivery
US9260693B2 (en) 2004-12-03 2016-02-16 Cytonome/St, Llc Actuation of parallel microfluidic arrays
US8114055B2 (en) * 2005-05-10 2012-02-14 Palyon Medical (Bvi) Limited Implantable pump with infinitely variable resistor
US8915893B2 (en) 2005-05-10 2014-12-23 Palyon Medical (Bvi) Limited Variable flow infusion pump system
US8211060B2 (en) * 2005-05-10 2012-07-03 Palyon Medical (Bvi) Limited Reduced size implantable pump
US7637892B2 (en) * 2005-05-10 2009-12-29 Palyon Medical (Bvi) Limited Variable flow infusion pump system
US8083710B2 (en) * 2006-03-09 2011-12-27 The Invention Science Fund I, Llc Acoustically controlled substance delivery device
US20070106277A1 (en) * 2005-11-09 2007-05-10 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Remote controller for substance delivery system
US9067047B2 (en) * 2005-11-09 2015-06-30 The Invention Science Fund I, Llc Injectable controlled release fluid delivery system
US8936590B2 (en) * 2005-11-09 2015-01-20 The Invention Science Fund I, Llc Acoustically controlled reaction device
US8992511B2 (en) * 2005-11-09 2015-03-31 The Invention Science Fund I, Llc Acoustically controlled substance delivery device
US7942867B2 (en) * 2005-11-09 2011-05-17 The Invention Science Fund I, Llc Remotely controlled substance delivery device
US8273071B2 (en) 2006-01-18 2012-09-25 The Invention Science Fund I, Llc Remote controller for substance delivery system
US9254256B2 (en) * 2005-11-09 2016-02-09 The Invention Science Fund I, Llc Remote controlled in vivo reaction method
US8273075B2 (en) * 2005-12-13 2012-09-25 The Invention Science Fund I, Llc Osmotic pump with remotely controlled osmotic flow rate
US20070179609A1 (en) * 2006-01-27 2007-08-02 Medicinelodge, Inc. Therapeutic agent eluding implant with percutaneous supply
US20080140057A1 (en) * 2006-03-09 2008-06-12 Searete Llc, A Limited Liability Corporation Of State Of The Delaware Injectable controlled release fluid delivery system
DE602007012417D1 (en) 2006-03-14 2011-03-24 Univ Southern California Mems device for drug release
WO2007115039A2 (en) 2006-03-30 2007-10-11 Valeritas, Llc Multi-cartridge fluid delivery device
ES2425769T5 (en) 2007-12-20 2017-07-28 University Of Southern California Apparatus for the administration of therapeutic agents
WO2009088608A2 (en) 2008-01-02 2009-07-16 The Regents Of The University Of Michigan Dual drug delivery device
EP2320989B1 (en) 2008-05-08 2015-03-11 MiniPumps, LLC Implantable pumps and cannulas therefor
US9849238B2 (en) 2008-05-08 2017-12-26 Minipumps, Llc Drug-delivery pump with intelligent control
ES2534865T3 (en) 2008-05-08 2015-04-29 Minipumps, Llc Drug delivery pumps
JP5758388B2 (en) 2009-08-18 2015-08-05 ミニパンプス， エルエルシー Electrolyte drug delivery pump with adaptive control
US8419673B2 (en) 2009-09-21 2013-04-16 Alcon Research, Ltd. Glaucoma drainage device with pump
US8545431B2 (en) * 2009-09-21 2013-10-01 Alcon Research, Ltd. Lumen clearing valve for glaucoma drainage device
US8721580B2 (en) * 2009-09-21 2014-05-13 Alcon Research, Ltd. Power saving glaucoma drainage device
US8257295B2 (en) 2009-09-21 2012-09-04 Alcon Research, Ltd. Intraocular pressure sensor with external pressure compensation
US9259530B2 (en) * 2009-11-25 2016-02-16 Medtronic, Inc. Implantable infusion device
US20110275987A1 (en) * 2010-04-20 2011-11-10 Minipumps, Llc Piston-driven drug pump devices
US8585631B2 (en) 2011-10-18 2013-11-19 Alcon Research, Ltd. Active bimodal valve system for real-time IOP control
US8753305B2 (en) * 2011-12-06 2014-06-17 Alcon Research, Ltd. Bubble-driven IOP control system
US8840578B2 (en) * 2011-12-09 2014-09-23 Alcon Research, Ltd. Multilayer membrane actuators
US8579848B2 (en) 2011-12-09 2013-11-12 Alcon Research, Ltd. Active drainage systems with pressure-driven valves and electronically-driven pump
US9622910B2 (en) 2011-12-12 2017-04-18 Alcon Research, Ltd. Active drainage systems with dual-input pressure-driven values
WO2013090231A1 (en) 2011-12-13 2013-06-20 Alcon Research, Ltd. Active drainage systems with dual-input pressure-driven valves
US9339187B2 (en) 2011-12-15 2016-05-17 Alcon Research, Ltd. External pressure measurement system and method for an intraocular implant
US8568360B2 (en) 2011-12-28 2013-10-29 Palyon Medical (Bvi) Limited Programmable implantable pump design
US9155653B2 (en) 2012-02-14 2015-10-13 Alcon Research, Ltd. Pressure-driven membrane valve for pressure control system
US8986240B2 (en) 2012-02-14 2015-03-24 Alcon Research, Ltd. Corrugated membrane actuators
US9381039B2 (en) 2012-03-21 2016-07-05 Medtronic, Inc. Filling methods and apparatus for implanted medical therapy delivery devices
US8652085B2 (en) * 2012-07-02 2014-02-18 Alcon Research, Ltd. Reduction of gas escape in membrane actuators
US9132034B2 (en) * 2012-10-01 2015-09-15 Alcon Research, Ltd. Valve position sensor
US9528633B2 (en) 2012-12-17 2016-12-27 Novartis Ag MEMS check valve
US9295389B2 (en) 2012-12-17 2016-03-29 Novartis Ag Systems and methods for priming an intraocular pressure sensor in an intraocular implant
US9572712B2 (en) * 2012-12-17 2017-02-21 Novartis Ag Osmotically actuated fluidic valve
US9226851B2 (en) 2013-08-24 2016-01-05 Novartis Ag MEMS check valve chip and methods
US9289324B2 (en) 2013-08-26 2016-03-22 Novartis Ag Externally adjustable passive drainage device
US9283115B2 (en) 2013-08-26 2016-03-15 Novartis Ag Passive to active staged drainage device
US9603742B2 (en) 2014-03-13 2017-03-28 Novartis Ag Remote magnetic driven flow system
US9681983B2 (en) 2014-03-13 2017-06-20 Novartis Ag Debris clearance system for an ocular implant
US9655777B2 (en) 2015-04-07 2017-05-23 Novartis Ag System and method for diagphragm pumping using heating element
CN110180054A (en) * 2019-07-04 2019-08-30 山西医科大学 A kind of closed loop drug delivery systems

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0134614A1 (en) * 1983-08-15 1985-03-20 Vitafin N.V. Piezo-electrical micropump
US4687423A (en) * 1985-06-07 1987-08-18 Ivac Corporation Electrochemically-driven pulsatile drug dispenser
EP0387439A1 (en) * 1987-12-15 1990-09-19 Infusaid, Inc. Implantable infusion device
EP0450186A1 (en) * 1990-04-02 1991-10-09 Pudenz-Schulte Medical Research Corporation Medication infusion device with dose recharge restriction
US5281210A (en) * 1992-09-18 1994-01-25 Infusaid, Inc. Accumulator for implantable pump
EP0761256A2 (en) * 1995-09-01 1997-03-12 Strato/Infusaid Inc. Power supply for implantable device

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE512521C (en) * 1927-02-15 1930-11-13 Arthur John Holman Cinema projector with optical compensation
GB354742A (en) * 1930-03-05 1931-08-05 Cornelius John Sutton Improvements appertaining to petrol tanks for motor road vehicles
US4673391A (en) * 1983-05-31 1987-06-16 Koichi Sakurai Non-contact controlled micropump
JPH06200257A (en) * 1992-11-16 1994-07-19 Muneharu Ueda Apparatus for treating petroleum-derived polymer article
US5417235A (en) * 1993-07-28 1995-05-23 Regents Of The University Of Michigan Integrated microvalve structures with monolithic microflow controller
US5368704A (en) * 1993-08-06 1994-11-29 Teknekron Corporation Micro-electrochemical valves and method
US5643207A (en) * 1995-04-28 1997-07-01 Medtronic, Inc. Implantable techniques for infusing a therapeutic agent with endogenous bodily fluid

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0134614A1 (en) * 1983-08-15 1985-03-20 Vitafin N.V. Piezo-electrical micropump
US4687423A (en) * 1985-06-07 1987-08-18 Ivac Corporation Electrochemically-driven pulsatile drug dispenser
EP0387439A1 (en) * 1987-12-15 1990-09-19 Infusaid, Inc. Implantable infusion device
EP0450186A1 (en) * 1990-04-02 1991-10-09 Pudenz-Schulte Medical Research Corporation Medication infusion device with dose recharge restriction
US5281210A (en) * 1992-09-18 1994-01-25 Infusaid, Inc. Accumulator for implantable pump
EP0761256A2 (en) * 1995-09-01 1997-03-12 Strato/Infusaid Inc. Power supply for implantable device

Cited By (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8608713B2 (en) 1998-12-07 2013-12-17 C. R. Bard, Inc. Septum feature for identification of an access port
WO2003018089A1 (en) * 2001-08-31 2003-03-06 Institute Of Materials Research And Engineering Liquid delivering device
CN100356993C (en) * 2001-08-31 2007-12-26 新加坡科技研究局 Liquid delivering device
WO2005044342A1 (en) * 2003-11-07 2005-05-19 Agency For Science, Technology And Research Liquid housing chamber and liquid delivering device containing such chamber
US8585663B2 (en) 2005-03-04 2013-11-19 C. R. Bard, Inc. Access port identification systems and methods
US10265512B2 (en) 2005-03-04 2019-04-23 Bard Peripheral Vascular, Inc. Implantable access port including a sandwiched radiopaque insert
US10905868B2 (en) 2005-03-04 2021-02-02 Bard Peripheral Vascular, Inc. Systems and methods for radiographically identifying an access port
US10857340B2 (en) 2005-03-04 2020-12-08 Bard Peripheral Vascular, Inc. Systems and methods for radiographically identifying an access port
US10675401B2 (en) 2005-03-04 2020-06-09 Bard Peripheral Vascular, Inc. Access port identification systems and methods
US8382723B2 (en) 2005-03-04 2013-02-26 C. R. Bard, Inc. Access port identification systems and methods
US9474888B2 (en) 2005-03-04 2016-10-25 C. R. Bard, Inc. Implantable access port including a sandwiched radiopaque insert
US8603052B2 (en) 2005-03-04 2013-12-10 C. R. Bard, Inc. Access port identification systems and methods
US11077291B2 (en) 2005-03-04 2021-08-03 Bard Peripheral Vascular, Inc. Implantable access port including a sandwiched radiopaque insert
US8382724B2 (en) 2005-03-04 2013-02-26 C. R. Bard, Inc. Systems and methods for radiographically identifying an access port
US10238850B2 (en) 2005-03-04 2019-03-26 Bard Peripheral Vascular, Inc. Systems and methods for radiographically identifying an access port
US10179230B2 (en) 2005-03-04 2019-01-15 Bard Peripheral Vascular, Inc. Systems and methods for radiographically identifying an access port
US9682186B2 (en) 2005-03-04 2017-06-20 C. R. Bard, Inc. Access port identification systems and methods
US8939947B2 (en) 2005-03-04 2015-01-27 C. R. Bard, Inc. Systems and methods for radiographically identifying an access port
US8998860B2 (en) 2005-03-04 2015-04-07 C. R. Bard, Inc. Systems and methods for identifying an access port
US9603993B2 (en) 2005-03-04 2017-03-28 C. R. Bard, Inc. Access port identification systems and methods
US9603992B2 (en) 2005-03-04 2017-03-28 C. R. Bard, Inc. Access port identification systems and methods
US10625065B2 (en) 2005-04-27 2020-04-21 Bard Peripheral Vascular, Inc. Assemblies for identifying a power injectable access port
US10183157B2 (en) 2005-04-27 2019-01-22 Bard Peripheral Vascular, Inc. Assemblies for identifying a power injectable access port
US10780257B2 (en) 2005-04-27 2020-09-22 Bard Peripheral Vascular, Inc. Assemblies for identifying a power injectable access port
US8475417B2 (en) 2005-04-27 2013-07-02 C. R. Bard, Inc. Assemblies for identifying a power injectable access port
US10661068B2 (en) 2005-04-27 2020-05-26 Bard Peripheral Vascular, Inc. Assemblies for identifying a power injectable access port
US8545460B2 (en) 2005-04-27 2013-10-01 C. R. Bard, Inc. Infusion apparatuses and related methods
US10307581B2 (en) 2005-04-27 2019-06-04 C. R. Bard, Inc. Reinforced septum for an implantable medical device
US8641676B2 (en) 2005-04-27 2014-02-04 C. R. Bard, Inc. Infusion apparatuses and methods of use
US8641688B2 (en) 2005-04-27 2014-02-04 C. R. Bard, Inc. Assemblies for identifying a power injectable access port
US9937337B2 (en) 2005-04-27 2018-04-10 C. R. Bard, Inc. Assemblies for identifying a power injectable access port
US10016585B2 (en) 2005-04-27 2018-07-10 Bard Peripheral Vascular, Inc. Assemblies for identifying a power injectable access port
US10052470B2 (en) 2005-04-27 2018-08-21 Bard Peripheral Vascular, Inc. Assemblies for identifying a power injectable access port
US9421352B2 (en) 2005-04-27 2016-08-23 C. R. Bard, Inc. Infusion apparatuses and methods of use
US8805478B2 (en) 2005-04-27 2014-08-12 C. R. Bard, Inc. Methods of performing a power injection procedure including identifying features of a subcutaneously implanted access port for delivery of contrast media
US10092725B2 (en) 2006-11-08 2018-10-09 C. R. Bard, Inc. Resource information key for an insertable medical device
US9642986B2 (en) 2006-11-08 2017-05-09 C. R. Bard, Inc. Resource information key for an insertable medical device
US10556090B2 (en) 2006-11-08 2020-02-11 C. R. Bard, Inc. Resource information key for an insertable medical device
US9265912B2 (en) 2006-11-08 2016-02-23 C. R. Bard, Inc. Indicia informative of characteristics of insertable medical devices
WO2009053914A1 (en) * 2007-10-25 2009-04-30 Koninklijke Philips Electronics N.V. Implantable drug delivery system
US9579496B2 (en) 2007-11-07 2017-02-28 C. R. Bard, Inc. Radiopaque and septum-based indicators for a multi-lumen implantable port
US11638810B2 (en) 2007-11-07 2023-05-02 C. R. Bard, Inc. Radiopaque and septum-based indicators for a multi-lumen implantable port
US10086186B2 (en) 2007-11-07 2018-10-02 C. R. Bard, Inc. Radiopaque and septum-based indicators for a multi-lumen implantable port
US10792485B2 (en) 2007-11-07 2020-10-06 C. R. Bard, Inc. Radiopaque and septum-based indicators for a multi-lumen implantable port
US8932271B2 (en) 2008-11-13 2015-01-13 C. R. Bard, Inc. Implantable medical devices including septum-based indicators
US10773066B2 (en) 2008-11-13 2020-09-15 C. R. Bard, Inc. Implantable medical devices including septum-based indicators
US10052471B2 (en) 2008-11-13 2018-08-21 C. R. Bard, Inc. Implantable medical devices including septum-based indicators
US11890443B2 (en) 2008-11-13 2024-02-06 C. R. Bard, Inc. Implantable medical devices including septum-based indicators
US9248268B2 (en) 2009-11-17 2016-02-02 C. R. Bard, Inc. Overmolded access port including anchoring and identification features
US9079004B2 (en) 2009-11-17 2015-07-14 C. R. Bard, Inc. Overmolded access port including anchoring and identification features
US9717895B2 (en) 2009-11-17 2017-08-01 C. R. Bard, Inc. Overmolded access port including anchoring and identification features
US10912935B2 (en) 2009-11-17 2021-02-09 Bard Peripheral Vascular, Inc. Method for manufacturing a power-injectable access port
US10155101B2 (en) 2009-11-17 2018-12-18 Bard Peripheral Vascular, Inc. Overmolded access port including anchoring and identification features
US11759615B2 (en) 2009-11-17 2023-09-19 Bard Peripheral Vascular, Inc. Overmolded access port including anchoring and identification features
USD682416S1 (en) 2010-12-30 2013-05-14 C. R. Bard, Inc. Implantable access port
USD676955S1 (en) 2010-12-30 2013-02-26 C. R. Bard, Inc. Implantable access port
WO2021110801A1 (en) 2019-12-06 2021-06-10 Sanofi Dosing mechanism with rotational end stop mechanism for terminating dose dispense

Also Published As

Publication number Publication date
US6048328A (en) 2000-04-11
DE69902145D1 (en) 2002-08-22
EP1053036A1 (en) 2000-11-22
EP1053036B1 (en) 2002-07-17
AU2573499A (en) 1999-08-16
DE69902145T2 (en) 2003-03-20
WO1999038553A9 (en) 1999-10-21

Similar Documents

Publication Publication Date Title
US6048328A (en) Implantable drug infusion device having an improved valve
US9968741B2 (en) Valves, valved fluid transfer devices and ambulatory infusion devices including the same
EP1058565B1 (en) Implantable drug infusion device having a safety valve
US4447224A (en) Variable flow implantable infusion apparatus
US8679095B2 (en) Regulator
US5725017A (en) In-line pressure check valve for drug-delivery systems
US7867203B2 (en) Implantable pump with adjustable flow rate
US8114055B2 (en) Implantable pump with infinitely variable resistor
EP2280750B1 (en) Flow sensor controlled infusion device
US20050187515A1 (en) Reduced size programmable drug pump
US10004848B2 (en) Valves, valved fluid transfer devices and ambulatory infusion devices including the same
WO2006122330A2 (en) Implantable pump with infinitely variable resistor
EP2193275B1 (en) Two way accumulator programmable valve pump
US9259530B2 (en) Implantable infusion device
KR101961415B1 (en) Tubeless implantable drug infusion system

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/9-9/9, DRAWINGS, REPLACED BY NEW PAGES 1/8-8/8; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1999905609

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999905609

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1999905609

Country of ref document: EP